Focus on IL-6 Inhibitors for Optimizing Multimodal Management of RA
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
Course Videos
Video
What is the evidence that early aggressive treatment with biologics produces the best outcomes in patients with RA? Are the guidelines supportive of this?
Video
How should one optimally “sequence” therapy in patients who require biologic therapy? Is there a “one-sequence-fits-all” strategy? Or can one start with any of the biologic agents as an initial therapy in conjunction with methotrexate?
Video
Are there any biomarkers for RA severity that are uniquely predictive of responsiveness with IL-6 inhibitors?
Video
Similarly, what role do anti-CPP antibodies play in assessing undifferentiated arthritis? Are they predictive of responses with specific biologic agents? What are implications of ACPA positivity for IL-6 inhibitors?
Video
Can the Simplified Disease Activity Index (SDAI) or CDAI provide predictive information that guides aggressiveness of therapy for RA? Do you consider abnormal results sufficient to trigger biologic therapy?
Video
Do we currently have biomarkers in the setting of RA that will predict patient response to the range of agents — including inhibitors of IL-6, TNF and other signaling cytokines — currently used for RA?